Epidemiology and updated management for autoimmune liver disease

키워드

참고문헌 (15)

1. Atsumasa Komori, "Recent updates on the management of autoimmune hepatitis", Clinical and Molecular Hepatology, 27(1), pp.58~69 (2021), 대한간학회[DOI]
2. Lv T, "Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population", J Gastroenterol Hepatol, 34, pp.1676~1684 (2019)
3. Kim BH, "Populationbased prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea", PLoS One, 12, pp.e0182391~ (2017)
4. Hartl J, "Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis", J Hepatol, 62, pp.642~646 (2015)
5. Ichai P, "Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis", Liver Transpl, 13, pp.996~1003 (2007)
6. Mack CL, "Diagnosis and management of autoimmune hepatitis in adults and children : 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases", Hepatology, 72, pp.671~722 (2020)
7. Moriyama T, "NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity", Nat Genet, 48, pp.367~373 (2016)
8. Atsushi Tanaka, "Current understanding of primary biliary cholangitis", Clinical and Molecular Hepatology, 27(1), pp.1~21 (2021), 대한간학회[DOI]
9. Lu M, "Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment", Clin Gastroenterol Hepatol, 16, pp.1342~1350 (2018)
10. Kim KA, "Populationbased epidemiology of primary biliary cirrhosis in South Korea", Aliment Pharmacol Ther, 43, pp.154~162 (2016)
11. Honda A, "Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis", Hepatology, 70, pp.2035~2046 (2019)
12. Corpechot C, "A placebo-controlled trial of bezafibrate in primary biliary cholangitis", N Engl J Med, 378, pp.2171~2181 (2018)
13. Atsushi Tanaka, "IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis", Gut and Liver, 13(3), pp.300~307 (2019), 거트앤리버 소화기연관학회협의회[DOI]
14. 서니은, "Sclerosing Cholangitis: Clinicopathologic Features, Imaging Spectrum, and Systemic Approach to Differential Diagnosis", Korean Journal of Radiology, 17(1), pp.25~38 (2016), 대한영상의학회[DOI]
15. Imam MH, "High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis", Aliment Pharmacol Ther, 34, pp.1185~1192 (2011)

관련 논문AI추천